Amgen Inc. closed $84.79 short of its 52-week high ($346.85), which the company achieved on July 25th.

Amgen has a strong product portfolio, pipeline developments, and robust financial health. Read why AMGN stock is a Strong Buy ...

In the latest market close, Amgen (AMGN) reached $262.05, with a +1.34% movement compared to the previous day. This change outpaced the S&P 500's 1.11% loss on the day. Meanwhile, the Dow experienced ...

Truist lowered the firm’s price target on Amgen (AMGN) to $298 from $333 and keeps a Hold rating on the shares as part of a broader research ...

Shares of Amgen Inc. AMGN slipped 1.01% to $258.59 Monday, on what proved to be an all-around mixed trading session for the ...

Article analyzes Amgen's strong clinical progress and financials, recommending caution due to valuation and technical ...

Amgen Inc (AMGN) stock saw a decline, ending the day at $258.59 which represents a decrease of $-2.63 or -1.01% from the prior close of $261.22. The stock opened at $259.05 and touched a low of ...

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Hold rating on Amgen (AMGN – Research Report), with a ...

Amgen Inc.'s ( NASDAQ:AMGN ) dividend will be increasing from last year's payment of the same period to $2.38 on 7th ...

This top healthcare company trades at 13 times forward earnings. It has a diverse portfolio of products, yields 3.6% at the ...

Amgen (AMGN) concluded the recent trading session at $258.59, signifying a -1.01% move from its prior day's close.

Amgen’s bispecific T-cell engager (BiTE) led to an ORR of 41% in patients with extensive-stage small cell lung cancer.